

61)

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

PCT/EP 00/09558



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/16, A61L 25/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 97/44015</b> (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/GB97/01308 (22) International Filing Date: 14 May 1997 (14.05.97) (30) Priority Data: 9610340.3 17 May 1996 (17.05.96) GB 9615436.4 23 July 1996 (23.07.96) GB		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: ANDARIS LIMITED [GB/GB]; 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB). (72) Inventors: HEATH, David; Andaris Limited, 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB). MIDDLETON, Sarah, Margaret; Andaris Limited, 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		Published With international search report.  <i>US 70/089, 668</i>	

(54) Title: MICROPARTICLES AND THEIR USE IN WOUND THERAPY

(57) Abstract

Soluble microparticles comprising fibrinogen or thrombin, in free-flowing form. These microparticles can be mixed to give a dry powder, to be used as a fibrin sealant that is activated only at a wound site.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

MICROPARTICLES AND THEIR USE IN WOUND THERAPYField of the Invention

This invention relates to microparticles that may be produced by spray-drying, and to their therapeutic use. In particular, the invention relates to fibrin sealant.

Background of the Invention

Fibrin sealant is a biological adhesive composed of fibrinogen and thrombin which is used extensively to assist wound healing and to provide sutureless closure of surgical wounds. Fibrinogen is the main structural protein in blood, responsible for forming clots.

For clot formation to occur, fibrinogen must be proteolytically cleaved and converted into fibrin monomer by thrombin, a serine protease that is converted to its active form by Factor Xa. Fibrin monomers assemble into fibrils and eventually form fibres in a three-dimensional network. The formation of a clot also requires the activity of Factor XIII. Factor XIII is a serine protease which is converted to its active form by thrombin in the presence of calcium. Activated Factor XIII (FXIIIa) then converts the non-covalent bonds between the assembled fibrin monomers into covalent bonds by transamination. This renders the fibrin gel less susceptible to proteolytic digestion by plasmin and also increases the overall strength and stiffness of the gel. Fibrin gel is readily resorbed by enzymatic and phagocytic pathways.

To reproduce this coagulation process in the form of a biological adhesive, the fibrinogen component of fibrin sealant usually contains Factor XIII, and the thrombin component is prepared in calcium chloride solution. The two components are applied either sequentially or simultaneously to the repair site, typically by syringe or by spraying. Fibrin sealant readily adheres to wet surfaces and, once polymerised, becomes a semi-rigid, haemostatic, fluid-tight adhesive capable of holding tissues or materials in the desired configuration.

Currently, fibrin sealant products are applied to the wound site as solutions, e.g. using a dual syringe device, which mixes the fibrinogen and thrombin as they exit. The main drawback of such delivery systems is clot formation within the device, resulting in needle and tube blockages. The dual syringe systems are also awkward to fill and manipulate. Further, if there is inadequate mixing of the fibrinogen and thrombin solutions, only weak clots may form.

Many wound sites ooze, and this can result in significant accumulation of fluid at the site. When solutions of the components of fibrin sealant are applied to such sites, they are often flushed away.

US-A-4427651 discloses a sprayable preparation for accelerated haemostasis and optimised biochemical control of wound closure, containing a powdery mixture of 15-60% by weight of thrombin, 5-80% by weight of a desiccating and stabilising agent (albumin, globulin and/or fibrinogen), and 1-10% by weight of fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent which is used as a propellant.

WO-A-9213495 discloses a lyophilised fibrinogen powder prepared by precipitation, without control of particle size. The powder is usually hydrated prior to use, with the disadvantages described above. It is also proposed that the powder can be used directly when the vessel or wound to be closed is small, and the blood loss is not rapid. In this case, the reaction is dependent on the presence of endogenous thrombin. In larger wounds, the heavier blood flow will wash away the endogenous material, and clotting will not take place.

#### Summary of the Invention

It has now been realised that spray-drying is useful as a means to give novel, soluble microparticles (including microcapsules) comprising fibrinogen or thrombin.

Respective fibrinogen-containing and thrombin-containing soluble microparticles can be formulated

together, in stable, dry form. This formulation can be subsequently activated, as desired, to give a fibrin sealant that is useful in wound therapy and surgical repair. It can meet the primary objectives of achieving good flow properties, enhanced, effective delivery to the active site, and dissolution only at the site, not in the delivery system.

#### Description of the Invention

Microparticles comprising fibrinogen or thrombin may be prepared by the procedures described in WO-A-9218164, WO-A-9609814 and WO-A-9618388. These spray-drying and associated particle manipulation processes enable the production of soluble protein microcapsules with defined size distribution, e.g. of up to 50  $\mu\text{m}$  in diameter. For example, as described in those documents, the microparticles may be produced reproducibly, e.g. with 90% or more (by mass) up to 20  $\mu\text{m}$ , e.g. 1 to 10  $\mu\text{m}$ , or up to 5  $\mu\text{m}$ , in size, or of submicron size if desired.

Microparticles of the invention may be prepared by spray-drying a solution of the active component alone. An alternative procedure comprises co-spray-drying, in which fibrinogen or thrombin and another wall-forming material are formulated and spray-dried, to give a microparticle in which the active component is incorporated in the wall of the particle.

The fibrinogen or thrombin may be full-length or any active fragment thereof. Fragments are known; see Collier et al, J. Clin. Invest. 89:546-555 (1992). Fibrinogen raw material may be a frozen solution, although a lyophilised powder which requires reconstitution prior to spray-drying may be used.

The spray-drying of proteins in the presence of excipients such as sugars (e.g. sucrose, lactose or mannitol) or other proteins stabilises the protein of interest and also ensures its effective dilution where low doses are required. The sugar may have a beneficial effect, in wound therapy.

Suitable other proteins may be naturally-occurring or recombinant. They may act as "wall-forming materials", as described in WO-A-9218164, where various examples are given. A preferred material is HSA (human serum albumin).  
5 For example, fibrinogen is spray-dried alone or in the presence of varying amounts of excipients such as HSA (e.g. fibrinogen: HSA ratios of 1:1, 1:3, 3:1) and sugars (e.g. mannitol).

The microparticles of this invention may have the  
10 physical characteristics described in the three publications identified above, e.g. being smooth and spherical, although size is not so critical since respirability is not a consideration. Known conditions can be used to produce, for example, microparticles of, say, c.  
15 1.5  $\mu\text{m}$  or c. 10  $\mu\text{m}$  diameter, which can ensure optimum recovery of either of the two proteins of interest.

It has been found that microparticles produced by spray-drying fibrinogen are surprisingly active and soluble. The use of spray-dried fibrinogen preparations  
20 may therefore be particularly advantageous in the hospital setting, where the solubilisation of freeze-dried fibrinogen can take 15 minutes or more, and usually requires heating. This is a rate-limiting step, and can cause considerable delay in the administration of fibrin  
25 sealant preparations to patients.

The concentration of the thrombin component in fibrin sealant is relatively low (e.g. 150  $\mu\text{g}$  thrombin per 40 mg fibrinogen). Preferably, therefore, thrombin is spray-dried with excipients such as HSA, sucrose, lactose or  
30 mannitol in varying proportions. This provides a homogeneous formulation, as described in more detail in Application No. PCT/GB97/00953.

Calcium ion, e.g. as calcium chloride, may be incorporated in the thrombin feedstock. Alternatively,  
35 calcium chloride may be added to the microcapsules after processing.

Microparticles of the invention may be sterilised, if necessary or desired. Sterile processing,  $\gamma$ -irradiation and ethylene oxide are examples of suitable techniques.

Although the components of the microcapsules in a fibrin sealant of the invention are preferably water-soluble, and the microparticles are preferably obtained by spray-drying a suitable solution, the microparticles that are obtainable may be free-flowing, discrete and substantially anhydrous. This means that the components of fibrin sealant in accordance with this invention are not activated until they are wetted, e.g. by coming into contact with liquid at a wound site. The active components may therefore be delivered as a dry mixture, although separate application of the different microparticles is also envisaged.

A dry powder fibrin sealant product may be of particular value where application to a large surface area is required. This includes surgery and repair of traumatic injuries to various organs such as the liver and spleen. A further advantageous application is in skin grafting for burns patients, and specifically where skin epidermal sheets are cultured *in vitro* and then transferred to the wound site. The use of fibrin sealant in the latter indication has proved to be particularly effective in patients with extensive burns, providing a biocompatible anchorage for skin grafts. It may also be suitable in the treatment of topical ulcers.

Products of the invention may be substantially dry. This means that they can be formulated with absorbent materials which, *inter alia*, can have the advantage over liquid fibrin sealants of drying and concentrating the product at the site of action, e.g. for haemostasis. A suitable such material is carboxymethylcellulose.

A NO scavenger may also be included in the formulation or, more generally, any material that promotes the aggregation of clots, inhibits their breakdown, or inhibits fibrin lysis. A material such as albumin has SH groups.

These may remove NO from the site of aggregation, and thus increase clot formation.

As described in more detail in WO-A-9609814, spray-dried microparticles may retain functional groups available for the binding of therapeutic agents. In this invention, a drug may be bound to the microparticles, if desired at the site of application. Thus, for example, a cytotoxic drug may be used where it is desired to treat skin cancer.

Other drugs that may be included in products of the invention, e.g. those containing fibrinogen, are coagulation factors such as Factors VII, VIII, IX, X and XIII, and von Willebrand's factor. This may be incorporated by co-spray-drying.

It has recently been observed that denatured albumin microbubbles preferentially attach themselves to damaged endothelium. This suggests that products of the invention will accumulate at wound sites, not only because of the activation of fibrinogen but also if there is an albumin component of the microparticle.

The following Example illustrates the invention.

Example

A fibrin sealant was prepared. This comprised a dry powder blend of microparticles respectively comprising fibrinogen and thrombin.

Fibrinogen (SNBTS) was formulated with 600 mg sucrose. Spray-drying was performed using a Mini Spray Dryer with a collecting vessel. The conditions were as follows:

Inlet Temperature:	100°C
Outlet Temperature:	65°C
Atomisation Pressure:	1.0 bar
Atomisation Type:	Schlick 970/0
Feed Rate:	1 g/min

A 20% final excipient loading was achieved. The activity detected using a kinetic assay was 13.88 mg/100



mg. The theoretical activity is 10 mg/100 mg. This indicated full retention of the fibrinogen bioactivity.

5 Separately, 1 g D-mannitol (Roquette, ESEX4) was dissolved in 10 ml of 40 mM  $\text{CaCl}_2$ . The resultant solution was used to reconstitute 1 vial of thrombin (SNBTS). The spray-drying conditions used were as above, except that the outlet temperature was c. 62°C, and the feed rate was reduced to 0.75 g/min.

10 A thrombin clotting assay revealed a thrombin activity of 91.86 units/100 mg. This compared favourably with the theoretical activity, of 93 units/100 mg.

The respective microparticles containing fibrinogen and thrombin were mixed to form a 50:50 blend, in a glass vial. The vial was placed on a roller mixer for 20 min.

15 The blend was evaluated in a meat adhesion assay, in various blend sizes. Each assay requires two sections of liver (2.5 cm x 2.5 cm). One liver section is stapled to a piece of cardboard. Both sections are wrapped in aluminium foil and incubated at 37°C for 20 minutes.

20 The loose liver section is threaded with cotton. A solution of 5% human serum albumin is applied to the surface of both liver sections, followed by the dry powder blend of fibrinogen and thrombin (fibrin sealant). The two liver sections are placed together and incubated at 37°C  
25 for 10 minutes.

The liver sections are then suspended from a clamp, and a hook is attached to the cotton. Weights are placed on the hook and the total weight suspended is used to calculate the tensile strength of the dry powder fibrin  
30 sealant blend in  $\text{mg/mm}^2$ . Results are given in the following Table.

Blend Size (mg)	Fibrinogen (mg)	Thrombin (units)	Tensile Strength (mg/mm <sup>2</sup> )
0	0	0	0
100	5	45	29.6
200	10	90	23.7
300	15	135	36.0
400	20	180	46.4
500	25	225	50.6

5

10

CLAIMS

1. Soluble microparticles comprising fibrinogen or thrombin, in free-flowing form.
2. Microparticles according to claim 2, comprising thrombin and also calcium ion.
3. Microparticles according to claim 1, comprising fibrinogen.
4. Microparticles according to any preceding claim, obtainable by spray-drying.
5. Microparticles according to any preceding claim, comprising albumin as a wall-forming material.
6. Microparticles according to any preceding claim, additionally comprising a carbohydrate.
7. Microparticles according to any preceding claim, up to 50  $\mu\text{m}$  in size.
8. Microparticles according to claim 7, of which at least 90% by mass are 10 to 20  $\mu\text{m}$  in size.
9. A dry mixture of soluble microparticles according to any preceding claim, respectively containing fibrinogen and thrombin.
10. A product comprising first and second microparticles according to any of claims 1 to 8, respectively containing fibrinogen and thrombin, as a combined preparation for simultaneous use in wound therapy or surgical repair.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 97/01308

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/16 A61L25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 444 692 A (MOCHIDA PHARMACEUTICAL CO) 4 September 1991	1,6
Y	see page 6, line 1 - line 53 ---	4,5,8
X	DATABASE WPI Week 9618 Derwent Publications Ltd., London, GB; AN 91-300974 XP002028108 & JP 08 053 365 A (DOJIN IYAKU KAKO KK ET AL.), 27 February 1996 see abstract ---	1
X	WO 92 13495 A (FIBRATEK, INC.) 20 August 1992 cited in the application see page 2, line 20 - line 29 see page 11, line 27 - line 34 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

Date of the actual completion of the international search

20 August 1997

Date of mailing of the international search report

01.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Benz, K

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 97/01308

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 427 651 A (STROETMANN) 24 January 1984 cited in the application see the whole document ---	1-10
A	US 4 752 466 A (SAFERSTEIN ET AL.) 21 June 1988 see the whole document see column 6, line 66 - column 7, line 15 ---	1
A	EP 0 196 813 A (EUROCELTIQUE SA) 8 October 1986 see the whole document ---	1-8
Y	WO 95 31479 A (INHALE THERAPEUTIC SYSTEMS, INC.) 23 November 1995 see page 12; example 3 see page 13 - page 14; example 5 see claims 1,3-8,17,19-23 -----	4,5,8

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/01308

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 444692 A	04-09-91	JP 3255035 A	13-11-91
		JP 8013750 B	14-02-96
		AT 116858 T	15-01-95
		AU 643753 B	25-11-93
		AU 7199291 A	05-09-91
		CA 2037325 A	02-09-91
		DE 69106549 D	23-02-95
		DE 69106549 T	22-06-95
		ES 2069761 T	16-05-95
		US 5149540 A	22-09-92
WO 9213495 A	20-08-92	AU 1461592 A	07-09-92
US 4427651 A	24-01-84	EP 0068047 A	05-01-83
		EP 0068048 A	05-01-83
		EP 0068149 A	05-01-83
		JP 1018054 B	03-04-89
		JP 58038216 A	05-03-83
		JP 1018055 B	03-04-89
		JP 58038217 A	05-03-83
		JP 58036545 A	03-03-83
		JP 61039824 B	05-09-86
		JP 61178927 A	11-08-86
		US 4427650 A	24-01-84
		US 4442655 A	17-04-84
US 4752466 A	21-06-88	NONE	
EP 196813 A	08-10-86	NL 8500774 A	16-10-86
		CA 1260834 A	26-09-89
		IE 58876 B	01-12-93
		JP 7045406 B	17-05-95
		JP 61215324 A	25-09-86
		US 4725434 A	16-02-88
WO 9531479 A	23-11-95	AU 2514295 A	05-12-95
		CA 2190502 A	23-11-95
		EP 0759939 A	05-03-97